We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Fibrocell

News List

Fibrocell, Castle Creek Enter Collaboration contractpharma
April 16, 2019
To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)...
Fibrocell Announces FDA Fast Track Designation of FCX-013 americanpharmaceuticalreview
September 06, 2018
Fibrocell Science announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma, a chronic, debilitating genet
Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market firstwordpharma
May 30, 2018
EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases